Corporate pressrelease · October 24, 2023 · 6 min read

Targeting Endogenous Mechanisms of Brain Resilience in Alzheimer’s Disease

Alzheimer's disease Interim data p-tau217 Phase 2 PTX-101
All stories  →
Clinical December 2, 2025

p75 receptor modulation slows biomarkers and preserves visuospatial function

CTAD coverage reports p-tau217 and synaptic-proteome signals over 26 weeks.

Read release →
Clinical April 3, 2025

New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients

NIA summarizes safety and biomarker findings supporting larger LM11A-31 trials.

Read release →
Clinical February 11, 2016

Alzheimer’s from a New Angle

Dr. Frank Longo on hope, innovation, and a radical departure…

Read release →